Toni Weinschenk
Corporate Officer/Principal chez IMMATICS N.V.
Fortune : 3 M $ au 31/03/2024
Profil
Toni Weinschenk is the founder of Immatics Biotechnologies GmbH, which was founded in 2000.
He held the title of Chief Innovation Officer at the company.
He is also the founder of Immatics US, Inc., which was founded in 2015, where he holds the title of Chief Technology Officer.
Currently, Dr. Weinschenk is the Chief Innovation Officer at Immatics NV, starting in 2020.
Dr. Weinschenk obtained a doctorate degree from Eberhard Karls Universität Tübingen.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMATICS N.V.
0,31% | 31/01/2024 | 323 549 ( 0,31% ) | 3 M $ | 31/03/2024 |
Postes actifs de Toni Weinschenk
| Sociétés | Poste | Début |
|---|---|---|
| IMMATICS N.V. | Corporate Officer/Principal | 01/01/2020 |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Founder | 01/01/2000 |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Founder | 01/06/2015 |
Formation de Toni Weinschenk
| Eberhard Karls Universität Tübingen | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IMMATICS N.V. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Health Technology |
